Vieites Marisol, Smircich Pablo, Guggeri Lucía, Marchán Edgar, Gómez-Barrio Alicia, Navarro Maribel, Garat Beatriz, Gambino Dinorah
Cátedra de Química Inorgánica, Facultad de Química, Universidad de la República, Gral. Flores 2124, C. C. 1157, 11800 Montevideo, Uruguay.
J Inorg Biochem. 2009 Oct;103(10):1300-6. doi: 10.1016/j.jinorgbio.2009.02.011. Epub 2009 Mar 17.
In the search for new therapeutic tools against parasitic diseases caused by the Kinetoplastids Leishmania spp. and Trypanosoma cruzi, a novel gold(I) triphenylphosphine complex with the bioactive coligand pyridine-2-thiol N-oxide (mpo) was synthesized and characterized by using analytical and conductometric measurements, electrospray ionization-mass spectrometry (ESI) and electronic, FTIR and (1)H and (31)P NMR spectroscopies. A dinuclear structure is suggested for the complex. At a 1 microM concentration the complex induced in vitro after 30 min a potent leishmanicidal effect (LD(50)) against promastigotes of Leishmania (L.) mexicana while on Leishmania (V.) braziliensis with the same concentration only a leishmanistatic effect (IC(75)) was observed 48 h after treatment. Similar differential susceptibilities were also found when testing the ligand mpo, but at a higher dose (5 microM). In addition, the compound showed growth inhibitory effect on Dm28c T. cruzi epimastigotes in culture (IC(50) 0.09 microM), being even more active than the anti-trypanosomal reference drug Nifurtimox (IC(50) 6 microM). DNA interaction studies showed that this biomolecule does not constitute a main target for the mpo complex currently tested. Instead, the significant potentiation of the antiproliferative effect against both Leishmania species and T. cruzi could be associated to the inhibition of NADH fumarate reductase, a kinetoplastid parasite-specific enzyme absent in the host. Furthermore, due to its low unspecific cytotoxicity on mammalian cells (J774 macrophages), the new gold complex showed a selective anti-parasite activity. It constitutes a promising new potent chemotherapeutic alternative to be evaluated in vivo in experimental models of leishmaniasis and Chagas disease.
在寻找针对由动基体利什曼原虫属和克氏锥虫引起的寄生虫病的新治疗工具时,合成了一种新型的金(I)三苯基膦配合物,其生物活性共配体为吡啶-2-硫醇N-氧化物(mpo),并通过分析和电导测量、电喷雾电离质谱(ESI)以及电子、傅里叶变换红外光谱(FTIR)和氢核磁共振(1H)及磷核磁共振(31P)光谱对其进行了表征。推测该配合物具有双核结构。在1微摩尔浓度下,该配合物在30分钟后对墨西哥利什曼原虫前鞭毛体具有体外强效杀利什曼原虫作用(半数致死剂量(LD50)),而在相同浓度下,对巴西利什曼原虫在处理48小时后仅观察到利什曼原虫生长抑制作用(半数抑制浓度(IC75))。在测试配体mpo时也发现了类似的差异敏感性,但剂量更高(5微摩尔)。此外,该化合物对培养中的克氏锥虫Dm28c型上鞭毛体具有生长抑制作用(半数抑制浓度(IC50)为0.09微摩尔),甚至比抗锥虫参考药物硝呋替莫(半数抑制浓度(IC50)为6微摩尔)更具活性。DNA相互作用研究表明,这种生物分子不是目前测试的mpo配合物的主要靶点。相反,对两种利什曼原虫和克氏锥虫的抗增殖作用的显著增强可能与烟酰胺腺嘌呤二核苷酸(NADH)延胡索酸还原酶的抑制有关,该酶是宿主中不存在的动基体寄生虫特异性酶。此外,由于其对哺乳动物细胞(J774巨噬细胞)的非特异性细胞毒性较低,这种新型金配合物显示出选择性抗寄生虫活性。它构成了一种有前景的新型强效化疗替代物,有待在利什曼病和恰加斯病的实验模型中进行体内评估。